- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01708356
Cycling, Air Pollution and Health (CAPaH)
Introduction: Cycling is currently promoted at the municipal, provincial and national level as a form of active transportation that increases physical activity while at the same time reducing traffic congestion, traffic-related air pollution and greenhouse gas emissions. While at a population level the health benefits of exercise via cycling are estimated to substantially exceed any health impacts related to air pollution exposure and injuries from traffic accidents , cyclists are known to experience elevated exposures to traffic-related air pollutants. Combined with exposure to elevated concentrations of air pollutants, cyclists also are subject to substantially increased inhaled doses due to their level of exertion and consequently increased inhalation rate. Therefore, given that cyclists experience exposures to relatively high concentrations of traffic-related air pollutants and that their inhalation of these pollutants is increased, it is important to evaluate the potential health impacts of this scenario. Research on the potential health impacts related to exercise (cycling) and urban air pollution exposure can help inform public communication strategies related to air quality and its health impacts. In addition, as our previous work suggests substantial variability in air pollution exposures to cyclists that is related to the route type and the levels of traffic along cycling routes, there is potential for transportation planners to promote increased cycling by enhancing infrastructure while at the same time developing routes that also minimize exposure to air pollution. The cyclist population is also interested in information regarding the air pollution exposures and potential health impacts related to cycling.
The objective of this study is to investigate the relationship between traffic-related air pollution exposure, and respiratory and cardiovascular health impacts in commuting cyclists. Specifically, the investigators propose to:
- determine commuting cyclists' exposure to traffic-related air pollutants (PM 2.5, PM10, ultrafine particulate, black carbon) while cycling along two different bicycle routes in the city of Vancouver;
- estimate the pollutant dose received by each cyclist, and relate this to the health effects observed; and
- determine if there is a change in lung function, endothelial function, and C-reactive protein level related to the level of air pollution exposure and dose
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z3
- Air Pollution Exposure Lab, Vancouver General Hospital through the School of Population and Public Health, University of British Columbia
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 19- 39
- male or female
- able to bicycle comfortably on city streets for 1 hour
Exclusion Criteria:
- Smokers of any substance (smoking more than 1x every 2 weeks)
- Must be of height to safely ride a test bike (<5'2", >6'5" )
- Diagnosed asthma or active allergy (hav fever) symptoms
- Irregular menstrual cycle, pregnant, breastfeeding, non-monocyclic contraceptive medication or device
- Taking medication for heart or lung condition
- Answers yes to any questions on physical activity readiness questionnaire (PAR-Q)
- requires pain medication daily
- visual or hearing impairment that prevents safe cycling on streets with motor vehicles
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Normal cycling
Cycling on a residential and downtown route (crossover design)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in endothelial function, as measured by peripheral arterial tonometry (EndoPAT) score of reactive hyperemia index (RHI)
Tidsramme: Baseline (1 hour pre-expousre) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-expousre) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in lung function (using spirometry to assess lung function values)
Tidsramme: Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in blood levels of C-reactive protein (a marker of systemic inflammation)
Tidsramme: Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
|
Change in blood levels of Interleukin-6 (a marker of systemic inflammation)
Tidsramme: Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
|
Change in blood levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG)(a marker of oxidative stress)
Tidsramme: Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Michael Brauer, ScD, The University of British Columbia
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- H10-00902
- H1008-111481/001/XSB (Annen identifikator: UBC CREB)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Endotelial dysfunksjon
-
University of LeipzigHar ikke rekruttert ennåImpact of Iridotomy/Iridectomy Size on Postoperative Pupillary Block and Dysphotopsia Following DMEKDysfotopsi | Descemet Membrane Endothelial Keratoplasty (DMEK) | Pupillary Block After DMEK | Laser Iridotomy / Surgical Iridectomy
-
Oslo University HospitalRekrutteringDescemet Stripping Automated Endothelial Keratoplasty (DSAEK) | Descemet Membrane Endothelial Keratoplasty (DMEK)Norge
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense... og andre samarbeidspartnereHar ikke rekruttert ennåLeverfibrose/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitt | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpania
-
Assiut UniversityUkjentPacemaker Lead DysfunctionItalia
-
Bursa Postgraduate HospitalFullførtPacemaker Lead Dysfunction | Manuell trekkraft
-
Rivus Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittForente stater
-
University of ChicagoFullførtICD | Enhetsfeil | Pacemaker Lead DysfunctionForente stater
-
Madrigal Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittForente stater
-
Shanghai East HospitalRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittKina
-
Southern California Institute for Research and...Har ikke rekruttert ennåMASH - Metabolic Dysfunction-Associated Steatohepatitt
Kliniske studier på Cycling on a residential route
-
University of Michigan Rogel Cancer CenterAktiv, ikke rekrutterendeAdenokarsinom i bukspyttkjertelen | Pankreatisk nevroendokrin svulst | Pankreas nevroendokrint karsinom | Adenosquamous karsinom | Gastrointestinal nevroendokrin svulst | Gastrointestinalt nevroendokrint karsinom | Nevroendokrint prostatakarsinomForente stater
-
Trustees of Dartmouth CollegeRekrutteringPlacebo effekt | Forventninger | Negativ affektivitet | Ikke-invasiv hjernestimuleringForente stater
-
Onconova Therapeutics, Inc.FullførtAvansert solid svulst | HepatomForente stater
-
elbion AGAvsluttetPanikklidelseTyskland, Nederland
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)AvsluttetKastrasjonsresistent prostatakarsinom | Metastatisk prostatakarsinom | Stage IVB prostatakreft AJCC v8 | Kastrasjonsnivåer av testosteron | Prostatakarsinom Metastatisk i beinetForente stater
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk bukspyttkjerteladenokarsinom | Stage IV Bukspyttkjertelkreft AJCC v6 og v7 | Trinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatisk Gastroøsofageal Junction Adenocarcinoma | Metastatisk kolorektalt karsinom | Metastatisk malignt... og andre forholdForente stater
-
Thomas Jefferson UniversityAbbVieFullførtMyelodysplastisk syndrom | Tilbakevendende myelodysplastisk syndrom | Refraktært myelodysplastisk syndromForente stater
-
National Cancer Institute (NCI)FullførtStadium IV Ovariekimcelletumor | Tilbakevendende kimcelletumor i eggstokkene | Stadium III testikkelkreft | Tilbakevendende ondartet testikkel-kimcellesvulst | Tilbakevendende Extragonadal Seminom | Tilbakevendende ondartet ekstragonadal kimcellesvulst | Tilbakevendende ondartet ekstragonadal ikke-seminomatøs... og andre forholdForente stater
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAvsluttetPrimær myelofibrose | Anemi | Tilbakevendende Hodgkin-lymfom | Refraktært Hodgkin-lymfom | Anatomisk stadium IV brystkreft AJCC v8 | Tilbakevendende akutt myeloid leukemi | Tilbakevendende myelodysplastisk syndrom | Refraktær Akutt Myeloid Leukemi | Refraktær kronisk myelomonocytisk leukemi | Refraktært myelodysplastisk... og andre forholdForente stater
-
Sidney Kimmel Cancer Center at Thomas Jefferson...FullførtAdenokarsinom i bukspyttkjertelen | Ikke-opererbart bukspyttkjertelkarsinom | Tilbakevendende bukspyttkjertelkarsinom | Stadium III Bukspyttkjertelkreft | Stadium IV BukspyttkjertelkreftForente stater